206 results
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ceftriaxone, Sulbactam
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-001568-PIP03-14, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for solution for injection or infusion
Decision date: 09/03/2015, Last updated: 24/03/2015, Compliance check: XKey facts Ceftriaxone Sulbactam Infectious diseasesP/0054/2015EMEA-001568-PIP03-14 … deferral for ceftriaxone / sulbactam (EMEA-001568-PIP03-14) PDF … investigation plan: Ceftriaxone / sulbactam for treatment of bacterial … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Durlobactam / sulbactam (SUL-DUR)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-002807-PIP01-20, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for solution for injection
Decision date: 22/12/2020, Last updated: 20/09/2021, Compliance check: Xtive substance Durlobactam / sulbactam (SUL-DUR) Therapeutic area … deferral for durlobactam / sulbactam (SUL-DUR) (EMEA-002807-PIP01-20 … deferral for durlobactam / sulbactam (SUL-DUR) (EMEA-002807-PIP01-20 … -
List item
National expert: Irene Bidault, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 80.07 KB | PDF
- Curriculum Vitae - 16.59 KB | PDF
PDF icon application/pdf ibidault_CV_en.pdf Declaration of interests … PDF icon application/pdf ibidault_DI_en.pdf … -
List item
Human medicine European public assessment report (EPAR): Tagrisso
osimertinib mesilate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 01/02/2016,
, Revision: 15, Authorised, Last updated: 07/04/2022
-
List item
Orphan designation: Acetylleucine for: Treatment of GM2 gangliosidosis
Date of designation: 12/12/2017, Positive, Last updated: 25/04/2019acetylleucine (also known as IBI1000) for the treatment of GM2 … acetylleucine (also known as IBI1000) for the treatment of GM2 … -
List item
Press release: Two new medicines for advanced kidney cancer
CHMP, Last updated: 22/07/2016recommendation is based is a Phase Ib/II trial involving 153 patients … complement data from the phase Ib/II trial. The opinions adopted … recommendation is based is a Phase Ib/II trial involving 153 patients … -
List item
National expert: Simona Kudeliene, Lithuania States Medicines Control Agency (updated)
- Declaration of interests - 79.84 KB | PDF
- Curriculum Vitae - 17.67 KB | PDF
-
List item
National expert: Paola Minghetti, Italian Medicines Agency (updated)
- Declaration of interests - 81.41 KB | PDF
- Curriculum Vitae - 62.13 KB | PDF
-
List item
National expert: Anna Wachnik-Święcicka, The Office for Registration of Medicinal Products, Medical Devices and Biocides (updated)
- Declaration of interests - 79.85 KB | PDF
- Curriculum Vitae - 19.15 KB | PDF
of infants2-12 months old (ibid.). 3. Wachnik A., Nagy K … zsiranyagcserere, patkanyban (ibid.). 8. Biro L., Rodics K … aktiyitasara patkany szerumban (ibid.). 11. Antal M., Wachnik … -
List item
National expert: Maria Grazia Evandri, Italian Medicines Agency (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 26.75 KB | PDF
-
List item
National expert: Maria Teresa Herdeiro, European Medicines Agency (updated)
- Declaration of interests - 79.8 KB | PDF
- Curriculum Vitae - 31.37 KB | PDF
Present Principal investigator iBiMED - University of Aveiro (Portugal) Research … Herdeiro Organisation/Company: iBiMED University of Aveiro Country … -
List item
National expert: Valentina Di Giovanni, Italian Medicines Agency (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 18.63 KB | PDF
company belonging to the IBIGEN group) (Italy) Implementation … company belonging to the IBIGEN group) (Italy) Involvment … -
List item
National expert: María Isabel Lucena, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 32.02 KB | PDF
-
List item
National expert: Piyush Jain, Federal Agency for Medicines and Health Products (updated)
- Declaration of interests - 81.03 KB | PDF
- Curriculum Vitae - 30.18 KB | PDF
Gianluca Matteoli, Sales Ibiza Martinez, Cintya Lopez-Lopez … Mondelaers, S.U., Matteoli, G., Ibiza Martinez, S., Lopez-Lopez … -
List item
National expert: Geert Molenberghs, European Medicines Agency (updated)
- Declaration of interests - 82.44 KB | PDF
- Curriculum Vitae - 139.67 KB | PDF
members of our department (I-BioStat) at Hasselt University and … -
List item
National expert: Ulrich Nordheim, Federal Institute for Drugs and Medical Devices (updated)
- Declaration of interests - 81.68 KB | PDF
- Curriculum Vitae - 18.54 KB | PDF
Cannabinoid Antagonist Ibipinabant (SLV319) Obesity, Diabetes … -
List item
Human medicine European public assessment report (EPAR): Supemtek (updated)
Influenza A virus subtype H1N1 haemagglutinin, recombinant, Influenza A virus subtype H3N2 haemagglutinin, recombinant, Influenza B virus Victoria lineage haemagglutinin, recombinant, Influenza B virus Yamagata lineage haemagglutinin, recombinant, Influenza, Human
Date of authorisation: 16/11/2020,
, Revision: 2, Authorised, Last updated: 28/07/2022
-
List item
Human medicine European public assessment report (EPAR): Poteligeo
Mogamulizumab, Sezary Syndrome; Mycosis Fungoides
Date of authorisation: 22/11/2018,, 
, Revision: 5, Authorised, Last updated: 28/04/2022
-
List item
Human medicine European public assessment report (EPAR): Tecentriq (updated)
atezolizumab, Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Urologic Neoplasms; Breast Neoplasms; Small Cell Lung Carcinoma
Date of authorisation: 20/09/2017, Revision: 19, Authorised, Last updated: 02/08/2022 -
List item
National expert: Guoda Radaviciute, Lithuania States Medicines Control Agency (updated)
- Declaration of interests - 79.8 KB | PDF
- Curriculum Vitae - 17.34 KB | PDF
evaluation of variations of type IB/IA and validation of type II … -
List item
Human medicine European public assessment report (EPAR): Kisqali (updated)
ribociclib succinate, Breast Neoplasms
Date of authorisation: 22/08/2017, Revision: 10, Authorised, Last updated: 26/07/2022 -
List item
Human medicine European public assessment report (EPAR): Polivy
polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020,, , 
, Revision: 4, Authorised, Last updated: 08/06/2022
-
List item
National expert: Christian Mayer, Austrian Medicines and Medical Devices Agency (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 18.22 KB | PDF
cyanobacterial cytochrome c oxidase. Ibidem pp.341-355 Projects Memberships Other … -
List item
Human medicine European public assessment report (EPAR): Wakix
pitolisant, Narcolepsy
Date of authorisation: 31/03/2016,, , Revision: 13, Authorised, Last updated: 09/12/2021
-
List item
Human medicine European public assessment report (EPAR): Zavicefta
avibactam sodium, ceftazidime pentahydrate, Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections
Date of authorisation: 23/06/2016,, Revision: 14, Authorised, Last updated: 05/07/2022